Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia

• Status: Enrolling by invitation
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to research the usefulness of PET/CT imaging for measuring brain inflammation and its relation to Alzheimer's Disease. Additionally, researchers as looking to learn more about the side effects of a new radioactive tracer (radiotracer) C-11 ER176.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Val Lowe

Criteria

Inclusion Criteria:

• Males or females 60 years of age or older.

• Meet the requirements for one of the four groups (CU A-, CU A+, MCI A+, AD A+).

• Undergoing neurologic evaluation procedures with cognitive testing in the MCSA or - ADRC for a minimum of about 3 years.

• All participants must have had an amyloid PiB PET scan and MRI brain scan within the previous 6 months.

• Capacity to sign consent or have a legally authorized representative to sign the consent.

Exclusion Criteria:

• Participants unable to lie down without moving for 20 minutes.

• Women who are pregnant or cannot stop breast feeding for 24 hours.

• Actively taking daily anti-inflammatory medications (NSAIDs, corticosteroids, etc.) except for a small control group.

• Generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning (only acute medication use as an exclusion so as to limit medication interaction but preserve possible chronic systemic inflammation interaction).

• Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc., since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI.